Company: STAA
Filing Date: 2025-12-09
Form Type: DFAN14A
Source: 0001213900-25-119731
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-12-09
Form: DFAN14A
Chunk 2
---
 BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE STOCKHOLDER MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREEN Proxy Card will be furnished to some
or all of the Company’s stockholders and will be, along with other relevant documents, available at no charge on the SEC’s
website at https://www.sec.gov/.

Information about the Participants and a description
of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants
with the SEC on November 21, 2025 and is available here.

Exhibit 1

<div align='center'>Broadwood Partners Responds to Alcon’s Increase to Proposed Acquisition Price of STAAR Surgical

Notes That Price Bump Is Further Evidence That the Original Sale Process Was Horribly Flawed and Failed to Maximize Shareholder Value

New Price Is Approximately Half the Price Offered by Alcon Twice in 2024; STAAR’s Projections Have Not Changed Materially

Continues to Urge STAAR Shareholders to Vote “ AGAINST” the Proposed Transaction</div>

NEW YORK--(BUSINESS WIRE)--Broadwood Partners,
L.P. and its affiliates (collectively, “Broadwood,” “we,” “us” or “our”) today responded
to the amended transaction terms of the proposed acquisition of STAAR Surgical Company (“STAAR” or the “Company”)
(NASDAQ: STAA) by Alcon Inc. (“Alcon”) (NYSE: ALC).

Broadwood, which owns 30.2% of STAAR’s outstanding
common stock, continues to oppose the proposed sale of the Company to Alcon and issued the following statement:

“STAAR spent months trying to
convince the Company’s shareholders that the Board had run a proper sale process and achieved a fair buyout price from Alcon. The
Board also claimed that the executives’ compensation packages were reasonable and had not created a misalignment of interests with
STAAR shareholders.

It is more evident than ever that none
of these claims were true and that this Board has been wrong more often than it has been right.

STAAR initially defended its absurd
sale process in which it shunned buyout interest from three parties and negotiated with just a single buyer with whom STAAR